Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primatesArticle Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] accompanied Blood clinical investigation Coverage COVID-19 COVID-19 pandemic COVID-19 vaccine cytokine release Diseases effective effort elicit Gam-COVID-Vac Health heterologous prime-boost IgA antibody IgG immune response Immunity immunization immunogenic immunogenicity Infection intranasal intranasal vaccine. intranasally K18-hACE2 transgenic mice less lung immunopathology mice mononuclear cell Mortality mucosal nasal mucosa neutralizing antibody non-human primate pandemic Peripheral blood Prevent proliferation protective immunity provided revaccination robust SARS-CoV-2 SARS-COV-2 infection SARSCoV-2 serum Sputnik V systemic and local the vaccine Transmission vaccination Vaccination strategy Vaccine vaccine candidate variants of concern virus virus infection virus spread [DOI] 10.1080/22221751.2022.2119169 PMC 바로가기
Head-to-head comparisons of the neutralizing antibody against SARS-CoV-2 variants elicited by four priming-boosting regimens4가지 프라이밍-부스팅 요법으로 유발된 SARS-CoV-2 변이체에 대한 중화 항체의 일대일 비교Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] comparison elicited neutralizing antibody regimen SARS-CoV-2 variant [DOI] 10.1080/22221751.2022.2095931 PMC 바로가기 [Article Type] Article
Serosurvey in SARS-CoV-2 inactivated vaccine-elicited neutralizing antibodies against authentic SARS-CoV-2 and its viral variantsArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome Administered Antibody neutralization BBIBP-CorV Beta booster vaccination circulating CoronaVac coronavirus Delta Eta Gamma humoral immune response immune immune response inactivated Inactivated vaccine individual Lineage lineages morbidity and mortality Mutation neutralization neutralization titer neutralize neutralized Neutralizing Neutralizing antibodies neutralizing antibody Neutralizing antibody response omicron reduce SARS-CoV-2 SARS-CoV-2 variant second vaccination serum sample significantly lower the SARS-CoV-2 vaccine dose variant viral variant Viral variants Viral variants. virus virus strain viruses wild-type [DOI] 10.1002/jmv.28049 PMC 바로가기
Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COV2.S vaccinesArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] Ad26.COV2.S Ad26.COV2.S vaccine antibody B.1.1.529 B.1.1.7 B.1.351 B.1.617.2 Beta BNT162b2 BNT162b2 vaccine booster center contributed Control COVID-19 Delta dose Effectiveness elicited faster FIVE Gamma immunization moderate mRNA-1273 mRNA-based vaccine Mutation Neutralizing Neutralizing antibodies neutralizing antibody omicron P.1 postvaccination prevention Protein pseudovirus receiving recipient recommendation robust SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 variant subject Support vaccination Vaccine vaccine efficacy variants of concern variants of concern (VOCs). VoC VOCs wild type [DOI] 10.1002/jmv.28032 PMC 바로가기
Humoral responses after inactivated COVID-19 vaccination in individuals with and without prior SARS-CoV-2 infection: A prospective cohort studyArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] acute respiratory syndrome antibody asymptomatic infections benefit blood sample booster dose Clinical severity collected coronavirus coronavirus disease COVID-19 COVID-19 vaccination detectable dose evaluated Evidence first dose humoral humoral immune response Humoral immunity Humoral response inactivated Inactivated COVID-19 vaccine individual individuals infected individuals Infection median mild cases moderate multicenter NAb titer NAbs naïve individual naïve individuals natural infection Neutralizing Neutralizing activity neutralizing antibody omicron pan-immunoglobulins. participant prospective cohort study Protein receive recovered patient SARS-CoV-2 second dose seroconversion rate severity significantly single dose single vaccine the vaccine U/mL vaccination variant [DOI] 10.1002/jmv.28055 PMC 바로가기
Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccinationArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome addition adenoviral-vectored vaccine antibody AZD1222 binding antibody BNT162b2 booster booster vaccination Booster vaccine comparable Complete coronavirus Coronavirus 2019 COVID-19 demonstrated develop dose Effect enrolled enzyme-linked immunosorbent Heterologous highest immune evasion immune response Immunogenicity analysis individual induce interferon-γ Messenger RNA Mild moderate mRNA mRNA vaccine mRNA-1273 mutations NAb titer NAbs neutralization neutralize Neutralizing Neutralizing activity neutralizing antibody observé Omicron variant Omicron. overcome participant raise receive receiving reduction response Serious Adverse Events significant increase Spike protein T-cell activation T-cell Response T-cell responses vaccination Vaccine waning immunity was recorded were measured [DOI] 10.1002/jmv.28044 PMC 바로가기
Evaluation of humoral immune responses induced by different SARS-CoV-2 spike trimers from wild-type and emerging variants with individual, sequential, and combinational delivered strategiesArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome Antibody Response antibody response against autologous binding circulating coronavirus coronavirus disease COVID-19 Delta effective heterogenous homologous humoral immune response immunization immunogenicity indicated induce monovalent vaccine multivalent vaccine neutralizing antibody Neutralizing antibody response omicron produced regimen SARS-CoV-2 SARS-CoV-2 spike trimer significantly spike Spike protein spike trimer strain supported trimer Vaccination strategies Vaccination strategy Vaccine Vaccines variant Variant. variants viruses wild type wild-type [DOI] 10.1002/jmv.28081 PMC 바로가기
Evaluation of response to different COVID-19 vaccines in vaccinated healthcare workers in a single center in IranArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 진단, [키워드] adenoviral-vectored vaccine Administered administration age anti-SARS-CoV-2 Anti-spike anti-spike antibody antibody Antibody Response average blood sample calculated center coronavirus disease Covaxin COVID-19 COVID-19 infection COVID-19 vaccine Cutoff ELISA evaluated Frequency healthcare worker individual Iran men Neutralizing antibodies neutralizing antibody neutralizing antibody. outcome Oxford/AstraZeneca pandemic participant participated positive proportion second dose significantly higher single center Sinopharm Sputnik V vaccination Vaccine Vaccines [DOI] 10.1002/jmv.28029 PMC 바로가기
Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Article Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 비임상, 진단, 치료기술, 치료제, [키워드] acute respiratory syndrome Beta Blood caused clinically Concentration coronavirus COVID-19 creatine phosphokinase CT-P63 deaths declining Delta demonstrated detectable dose double-blind evaluated groups healthy volunteer Immunity in vitro in vivo Infection Infectious virus lung monoclonal monoclonal antibody morbidity and mortality mutated variant Neutralizing Neutralizing activity neutralizing antibody neutralizing antibody. omicron pandemic parallel-group participant peaked phase Placebo placebo-controlled Preclinical prevalent Prophylactic Randomized reduced respiratory tract Safe SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants of concern Serious Adverse Events significantly single ascending dose study drug TEAE titre Tolerability Transgenic mouse treated Treatment treatment-emergent adverse event vaccination variants variants of SARS-CoV-2 wild-type [DOI] 10.1080/22221751.2022.2117094 PMC 바로가기
Evaluation of the T cell and B cell response following the administration of COVID-19 vaccines in KoreaArticle Published on 2022-12-012023-07-10 Journal: Journal of microbiology, immunology, and infection [Category] COVID19(2023년), [키워드] booster COVID-19 Interferon-gamma (IFN-γ) neutralizing antibody vaccine. [DOI] 10.1016/j.jmii.2022.09.004 PMC 바로가기